XML 34 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation (Tables)
3 Months Ended
Mar. 31, 2023
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Summary of Stock Option Transations

The following table summarizes the stock option transactions for the 2006 Plan:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Options

 

 

 

Weighted Average Exercise Price

 

 

Weighted Average Remaining Contractual Term (years)

 

 

 

Aggregate Intrinsic Value (in thousands)

 

Outstanding at December 31, 2022

 

 

739,511

 

 

$

 

6.94

 

 

 

7.36

 

 

$

 

8,903

 

Assumed in the Merger

 

 

310,431

 

 

 

 

76.72

 

 

 

 

 

 

 

 

Granted

 

 

180,231

 

 

 

 

17.34

 

 

 

 

 

 

 

 

Outstanding at March 31, 2023

 

 

1,230,173

 

 

$

 

26.14

 

 

 

5.82

 

 

$

 

371

 

Vested and exercisable at March 31, 2023

 

 

941,638

 

 

$

 

30.53

 

 

 

5.82

 

 

$

 

371

 

Schedule of Assumptions Using Black-Scholes to Estimate Fair Value of the stock option grants

The following is the range of underlying assumptions in Black-Scholes to determine the fair value of the stock option grants for the three months ended March 31, 2023 and 2022:

 

 

 

Three Months Ended March 31,

 

 

2023

 

 

2022

Risk free interest rate

 

3.56%

 

 

1.62%-1.76%

Expected volatility

 

75%

 

 

88%

Expected term (years)

 

 

6.25

 

 

5.50-6.08

Expected dividend yield

 

0%

 

 

0%

Summary of Stock-Based Compensation Expense Recognized for Options and RSUs Granted

Stock-based compensation expense recognized for options and restricted stock units granted was as follows (in thousands):

 

 

 

Three Months Ended
March 31,

 

 

 

 

2023

 

 

2022

 

 

Research and development

 

$

2,080

 

 

$

224

 

 

General and administrative

 

 

9,046

 

 

 

111

 

 

Total stock-based compensation expense

 

$

11,126

 

 

$

335

 

 

The stock-based compensation expense includes one-time charges for the acceleration of vesting of the Graybug stock options at the date of the Merger of $1.9 million and $8.6 million in research and development and general and administrative expenses, respectively.

Schedule of Common Stock Reserved for Future issuance

Common stock reserved for future issuance consists of the following at March 31, 2023:

 

 

 

March 31,

 

 

 

2023

 

Common stock warrants

 

 

276,437

 

Stock options issued and outstanding

 

 

1,230,173

 

Shares available for issuance under the 2023 Plan

 

 

1,000,000

 

Shares available under the 2023 ESPP

 

 

65,000

 

Total

 

 

2,571,610